MedTrace Logo

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

NCT04610138 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2023-04-03

No results posted yet for this study

Summary

This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of enrollment.

Conditions

  • Covid19

Interventions

DRUG

CNM-ZnAg

ZnAg liquid solution

DRUG

Placebo

Water

Sponsors & Collaborators

  • ICL Pharma

    collaborator UNKNOWN

  • Azidus Brazil

    collaborator UNKNOWN

  • Clene Nanomedicine

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-05-28
Completion
2022-10-20

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610138 on ClinicalTrials.gov